Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05485168 · ClinicalTrials.gov registry record · NA
Combined Effects of Sequential Variety and Portion Size on Meal Intake of Women
A NA study, sponsored by Penn State University.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT05485168: Completed NA study, sponsored by Penn State University.
NCT05485168 is a NA study that has completed, run by Penn State University. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05485168, a NA study, has completed, sponsored by Penn State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
The primary purpose of this study is to investigate the combined effects of sequential meal variety and portion size on food intake at a meal. Additionally, other individual characteristics will be examined for their influence on the effects of simultaneous variety and portion size on meal intake.
Primary Outcome
Weight (grams) of all meal components consumed
Interventions
- OTHER Single-Food
- OTHER Small Portion
- OTHER Large Portion
- OTHER Sequential Variety
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-09-06 |
| Est. Completion | 2023-04-07 |
| Phase | NA |
What the finished NCT05485168 record still lists
NCT05485168 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Single-Food is the first listed.
NCT05485168 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05485168 about?
NCT05485168 is a clinical study titled "Combined Effects of Sequential Variety and Portion Size on Meal Intake of Women". The primary purpose of this study is to investigate the combined effects of sequential meal variety and portion size on food intake at a meal. Additionally, other individual characteristics will be examined for their influence on the effects of simultaneous variety and portion size on meal intake.
What is the current status of trial NCT05485168?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2022-09-06. Estimated completion is 2023-04-07.
What interventions are being tested in trial NCT05485168?
The interventions under investigation include: Single-Food (OTHER), Small Portion (OTHER), Large Portion (OTHER), Sequential Variety (OTHER).
Who is sponsoring clinical trial NCT05485168?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05485168's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI